Clinical Study
Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study
Table 4
Median CFT and macular volume variation during the follow-up.
| | | Screening | 15 days | 1 month | 2 months | 3 months | 6 months |
| | Median (range) CFT value (µm) | | Treatment group | 462 (395–600) | 474 (368–636) | 502 (366–651) | 322 (227–509) | 380 (191–566) | 335 (250–609) | | — | | | | | | | Control group | 354 (279–373) | 296 (244–339) | 330 (256–359) | 334 (262–336) | 318 (267–330) | 292 (243–336) | | — | | | | | | | Comparison between groups | | | | | | |
| | Median macular volume value (mm3) | | Treatment group | 9.7 (8.3–9.8) | 9.04 (8.12–9.67) | 9.0 (8.1–10.7) | 8.09 (7.73–8.95) | 8.78 (7.92–9.31) | 8,45 (7,8–9,63) | | — | | | | | | | Control group | 8.3 (8.0–8.4) | 8.09 (7.91–8.26) | 8.2 (7.9–8.4) | 8.19 (8.11–8.20) | 8.30 (8.09–8.40) | 8,24 (8,09–8,3) | | — | | | | | | | Comparison between groups | | | | | | |
|
|
IQR: interquartile range; CFT: central foveal thickness.
|
